Related Experiment Video
Updated: Nov 20, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[Research Progress of Small Molecule Anti-angiogenic Drugs in Non-small Cell Lung Cancer]
1Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Abstract:
Lung cancer is one of the cancers with the highest incidence in the world, and there is no standard treatment plan after second-line progression. Tumor angiogenesis has now been identified as an important therapeutic target for malignant tumors. Small molecule multi-target vascular kinase inhibitors can inhibit tumor angiogenesis by inhibiting angiogenesis-related signal pathways. At present, a lot of clinical trials of small molecule anti-angiogenic drugs for the treatment of non-small cell lung cancer (NSCLC) have been carried out, and some vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have been approved for the treatment of advanced NSCLC. Based on the development status of multiple small molecule anti-angiogenic drugs at home and abroad for the treatment of NSCLC, this article summarizes the efficacy and safety studies of multiple VEGFR-TKIs and fibroblast growth factor receptor (FGFR)-TKI single agents or combination treatments [including combined with chemotherapy, epidermal growth factor receptor (EGFR)-TKIs, immunotherapy, and radiotherapy, etc.] for NSCLC, and at the same time discussed the possible existence of VEGFR-TKIs drug resistance mechanisms and efficacy predictors, etc., and prospect the future development trend and potential problems of anti-vascular treatment of NSCLC, and provide new ideas for the follow-up precision and individualized treatment of lung cancer. .
Insights
Targeting tumor angiogenesis with small molecule inhibitors offers new treatment options for advanced non-small cell lung cancer (NSCLC) after standard therapies fail. Research reviews efficacy, safety, and resistance mechanisms of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) and fibroblast growth factor receptor (FGFR)-TKIs in NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Cancer Therapeutics
Background:
- Lung cancer has a high global incidence, with limited treatment options following second-line therapy failure.
- Tumor angiogenesis is a critical target for anti-cancer drug development.
- Small molecule multi-target kinase inhibitors show promise in inhibiting tumor angiogenesis.
Purpose of the Study:
- To review the efficacy and safety of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) and fibroblast growth factor receptor (FGFR)-TKI in non-small cell lung cancer (NSCLC).
- To explore combination therapies involving VEGFR-TKIs and FGFR-TKIs with chemotherapy, targeted agents, immunotherapy, and radiotherapy.
- To discuss drug resistance mechanisms, efficacy predictors, and future directions for anti-angiogenic therapy in NSCLC.
Main Methods:
- Comprehensive literature review of clinical trials and studies on small molecule anti-angiogenic drugs for NSCLC.
- Analysis of efficacy and safety data for VEGFR-TKIs and FGFR-TKIs as monotherapies and in combination regimens.
- Discussion of emerging concepts including drug resistance and predictive biomarkers.
Main Results:
- Several VEGFR-TKIs are approved for advanced NSCLC, demonstrating clinical benefit.
- Combination strategies (e.g., with chemotherapy, immunotherapy) are being investigated to enhance treatment outcomes.
- Fibroblast growth factor receptor (FGFR)-TKIs are also emerging as potential therapeutic agents.
Conclusions:
- Targeting tumor angiogenesis with VEGFR-TKIs and FGFR-TKIs represents a significant advancement in NSCLC treatment.
- Understanding resistance mechanisms and identifying predictive biomarkers are crucial for optimizing patient selection and treatment strategies.
- Future research should focus on personalized and combination approaches to improve outcomes in advanced NSCLC.
More Related Videos
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Mechanism of Angiogenesis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply